© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 08, 2020
Targeted Oncology, a multimedia resource that offers content and expert opinions on standard and emerging treatments in the oncology field, announces the addition of the Society of Hematologic Oncology to its Strategic Alliance Partnership program.
September 25, 2015
Failure-free survival (FFS) for patients with follicular lymphoma has had a lack of improvement, fueling interest in new treatment strategies that may offer promise for better outcomes.
September 24, 2015
Single-agent ibrutinib (Imbruvica) data showed durable responses in patients with untreated or relapsed/refractory chronic lymphocytic leukemia (CLL).
New combination strategies are required for heterogeneity of mantle cell lymphoma (MCL), in order to improve outcomes.
Clinical evaluation suggests a role for immune checkpoint inhibition in the treatment of patients with lymphomas, but early success has also raised many questions.